|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||3.95 / 9.10|
Investors considering a purchase of ChemoCentryx, Inc. stock, but cautious about paying the going market price of $6.88/share, might benefit from considering selling puts among the alternative strategies at their disposal.
ChemoCentryx, Jazz Pharmaceuticals, Ionis Pharmaceuticals and Zogenix were among the biotech stock movers in premarket trading Friday.
Company Reports at ASCO 2017 Gastrointestinal Cancers Symposium 24 Week Progression-Free Survival and 48 Week Overall Survival Data as it Continues to Follow Progress in Study Patients
Treatment of aHUS patients with CCX168 effective in reducing aHUS serum-induced thrombus formation
Company expects additional data including progression-free survival by the end of 2016
Investors in ChemoCentryx, Inc. saw new options become available this week, for the February 2017 expiration.
PRIME designation designed to provide path to expedite clinical development and accelerate marketing authorization applications